Careful choice of nanoparticles as targets and in drug delivery routes enhances therapeutic efficacy in cancer. This book discusses nanotechnological developments of interfering RNA-based nanoparticles and delivery vehicles, validated therapeutic RNAi-molecular target interactions, and explains the results of clinical and preclinical trials.